How long does 3-FA last?

The total duration of 3-FA via oral is 4 hours to 6 hours. Onset typically occurs within 20 minutes to 1 hour. Peak effects last 2 hours to 3 hours.

3-FA — SubstanceWiki

3-FA

Amphetamine, Substituted amphetamines · Stimulants

9 dangerous interactions — combining 3-FA with certain substances may be life-threatening.

See all

Stimulants(Amphetamine, Substituted amphetamines)

Quick Dosage

oral30–50 mg (common)

Total duration (oral)4hr–6hr

View full details

3-Fluoroamphetamine (3-FA) is a fluorinated analog of amphetamine in which a fluorine atom is placed at the 3-position (meta) of the phenyl ring. It belongs to the substituted amphetamine chemical class and is distinguished within the series by its position isomerism from 4-FA: while 4-fluoroamphetamine has significant entactogenic (MDMA-like) properties due to serotonin releasing activity, 3-FA is generally characterized as a more purely stimulant compound with primarily dopaminergic and noradrenergic activity.

Community reports describe 3-FA as producing focused stimulation, wakefulness, and mood elevation broadly comparable to amphetamine or 2-FMA, but with a somewhat shorter duration and slightly more pronounced euphoric quality than the ortho-substituted 2-FMA. It is considered to occupy a middle ground in the fluoroamphetamine series — less functionally "clean" than 2-FMA but less overtly entactogenic than 4-FA or 3-FMA. The onset is typically 30–60 minutes orally, with effects lasting 4–8 hours.

As with all research chemical stimulants, formal human pharmacological data for 3-FA are absent. The compound's effects are inferred from structural analogy, animal studies, and the substantial body of community self-reports accumulated in harm reduction forums. While the meta substitution is associated with less serotonergic releasing activity than the para position, the specific receptor binding profile of 3-FA has not been fully characterized.

How It Feels

The onset of 3-FA announces itself more boldly than its positional isomers. Within twenty to forty minutes of oral ingestion, a rising wave of confident energy sweeps through the body. The chest warms, the pulse quickens, and a distinct euphoria begins to bloom, a bright, upward-pulling mood elevation that carries with it a desire to move, talk, and engage. This is not the quiet utility of the 2-fluorinated variants but something more recreational, more insistent in its pleasures.

As the experience climbs toward its peak over the next hour, the euphoria intensifies into something genuinely compelling. Conversations become animated and feel deeply satisfying. Social confidence surges, self-consciousness retreats, and there is a powerful sense that the world is fundamentally good and interesting. Music sounds outstanding, with enhanced rhythm perception and an almost physical pleasure in bass frequencies. The body is buzzing with clean, directed energy, warm and light, limbs eager for movement. The jaw clenches with noticeable force, the pupils widen, and the mouth dries, but these physical markers feel like background noise against the foreground of stimulated wellbeing.

At the peak, typically one to two hours in, 3-FA delivers a classic recreational stimulant profile. The euphoria is robust, the energy is abundant, and the sociability is nearly irresistible. There is a moderate empathogenic edge, a warmth toward others that falls short of MDMA territory but clearly exceeds baseline. Physical restlessness is pronounced: sitting still feels unnatural, and the body craves dancing, walking, or animated gesturing. Heart rate and blood pressure are notably elevated, appetite is entirely absent, and body temperature runs warm.

The comedown begins around four to five hours in and arrives with more friction than the functional fluoroamphetamines. As the euphoria drains away, a restless dissatisfaction takes its place, a sense that the glow has been turned off too soon. Fatigue builds, the jaw finally unclenches, and a mild but definite irritability may color the remaining hours. Sleep is difficult for some time after the primary effects fade. The following day may carry a residual tiredness and slightly lowered mood, proportional to the degree of euphoria that was borrowed the night before.

Detection Methods

Standard Drug Panel Inclusion

3-FA (3-Fluoroamphetamine) is a fluorinated amphetamine analogue that is generally not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. The fluorine substitution on the phenyl ring alters the molecular structure sufficiently that most amphetamine-targeted antibodies in commercial immunoassays fail to recognize it. However, cross-reactivity varies between manufacturers and assay generations, so a false positive on the amphetamine channel cannot be entirely ruled out.

Urine Detection

Due to the structural similarity to amphetamine, 3-FA (3-Fluoroamphetamine) and its metabolites may persist in urine for approximately 2 to 4 days after a single dose. Chronic or heavy use can extend this window. The primary metabolites include deaminated and hydroxylated derivatives, though comprehensive metabolic profiling of 3-FA (3-Fluoroamphetamine) in humans remains limited. Standard immunoassay urine cups will typically return a negative result for 3-FA (3-Fluoroamphetamine) unless the specific assay has unusually broad cross-reactivity.

Blood and Saliva Detection

3-FA (3-Fluoroamphetamine) can be detected in blood and oral fluid for approximately 12 to 48 hours after ingestion. Blood testing is uncommon outside of clinical or forensic contexts. Oral fluid testing follows a similar window but is used primarily in roadside or workplace settings where immediate-use detection is the goal.

Hair Follicle Detection

Hair follicle analysis can theoretically detect 3-FA (3-Fluoroamphetamine) for up to 90 days. However, most commercial hair testing laboratories do not include fluorinated amphetamines in their standard panels. Detection requires specific method development using LC-MS/MS with reference standards for 3-FA (3-Fluoroamphetamine).

Confirmatory Testing

Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the definitive methods for confirming the presence of 3-FA (3-Fluoroamphetamine). These techniques can distinguish 3-FA (3-Fluoroamphetamine) from amphetamine, methamphetamine, and other substituted amphetamines with high specificity. Reference standards for 3-FA (3-Fluoroamphetamine) must be available to the testing laboratory for positive identification.

Reagent Testing

Marquis reagent produces no reaction or a faint orange-brown color with 3-FA (3-Fluoroamphetamine), which differs from the orange-to-brown response seen with standard amphetamine. Mecke reagent typically shows no reaction. Simon's reagent can help differentiate primary amines from secondary amines in the amphetamine class. Mandelin reagent may produce a faint green-brown color. These reagent responses help distinguish 3-FA (3-Fluoroamphetamine) from MDMA, methamphetamine, and cathinones but cannot confirm identity on their own.

Interactions

Substance	Status	Note
Atropa belladonna	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Datura	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Diphenhydramine	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Harmala alkaloid	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Peganum harmala	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
25x-NBOMe	Unsafe	—
2C-T-x	Unsafe	—
DOx	Unsafe	—
PCP	Unsafe	—
1,3-Butanediol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
25E-NBOH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-2	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-21	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-7	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increased cardiovascular strain and neurotoxicity risk
4-MMC	Caution	Increased cardiovascular strain and neurotoxicity risk
8-Chlorotheophylline	Caution	Increased cardiovascular strain and neurotoxicity risk
Adrafinil	Caution	Increased cardiovascular strain and neurotoxicity risk
Allylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ayahuasca	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Benzydamine	Caution	Increased cardiovascular strain and neurotoxicity risk
Bromantane	Caution	Increased cardiovascular strain and neurotoxicity risk
Cake	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Deschloroetizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Desomorphine	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
DET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increased cardiovascular strain and neurotoxicity risk
Diclazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
DiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DOM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Efavirenz	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephedrine	Caution	Increased cardiovascular strain and neurotoxicity risk
EPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Eszopiclone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Etizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Gaboxadol	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Hexedrone	Caution	Increased cardiovascular strain and neurotoxicity risk
Ibogaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lorazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Mephenaqualone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methallylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increased cardiovascular strain and neurotoxicity risk
Metizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Midazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Naloxone	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
Nicotine	Caution	Increased cardiovascular strain and neurotoxicity risk
Nifoxipam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Oxiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Pentobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenylpiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Psilocybin Mushrooms	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increased cardiovascular strain and neurotoxicity risk
SAMe	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Alcohol	Uncertain	—
Caffeine	Uncertain	—
Cannabis	Uncertain	—
Cocaine	Uncertain	—
GHB	Uncertain	—
Ketamine	Uncertain	—

Showing 69 key interactions out of 72 total.

Toxicity & Safety

Overview

The toxicity profile of 3-FA has not been formally studied in humans. Based on its structural class and inferred pharmacology (primarily dopaminergic/noradrenergic releasing agent with some serotonergic activity), it is expected to carry risks broadly similar to amphetamine, with the caveat that the serotonergic component introduces additional considerations.

Cardiovascular Risk

Sympathomimetic effects — elevated heart rate, blood pressure, vasoconstriction — are the primary acute physiological risk. These are comparable to or slightly greater than amphetamine at equivalent doses. Stimulant-naive individuals and those with cardiovascular conditions are at elevated risk.

Neurotoxicity

If 3-FA possesses meaningful serotonin releasing activity, repeated high-dose use may carry some serotonergic neurotoxicity risk, as has been documented for 4-FA and related compounds. The degree of this risk is unknown and highly dependent on dose, frequency, and individual susceptibility.

Psychological Risks

Standard stimulant class psychological risks apply: anxiety, agitation, paranoia at high doses, potential for stimulant psychosis with chronic heavy use, and depressive rebound during the comedown period.

Dependence

Dopaminergic releasing agents carry meaningful physical and psychological dependence potential. While 3-FA lacks the recreational profile of 4-FA, compulsive use patterns can develop, particularly in individuals with histories of stimulant use disorders.

Addiction Potential

moderately addictive with a high potential for abuse

Overdose Information

Stimulant overdose from 3-FA is a medical emergency primarily involving cardiovascular and neurological toxicity.

Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.Emergency response:

Call emergency services immediately
Keep the person cool (remove excess clothing, apply cool water)
If seizures occur, protect the head and clear the area of hard objects
If the person loses consciousness, place in recovery position
Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionalsPrevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.

Full	develops with prolonged and repeated use
Half	3 - 7 days
Zero	1 - 10 days

3-FA

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(4)

Cognitive & Perceptual Effects

Cognitive(4)

Pharmacology

Mechanism of Action

Receptor Profile

Pharmacokinetics

Detection Methods

Standard Drug Panel Inclusion

Urine Detection

Blood and Saliva Detection

Hair Follicle Detection

Confirmatory Testing

Reagent Testing

Interactions

History

Development and Emergence

Position in the Fluoroamphetamine Series

Regulatory Landscape

Harm Reduction

Dose Reference Points

Timing

Avoid Frequent Use

Dangerous Combinations

Test Your Substance

Toxicity & Safety

Overview

Cardiovascular Risk

Neurotoxicity

Psychological Risks

Dependence

Addiction Potential

Overdose Information

Dangerous Interactions

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (9)

Community Discussions (2)

See Also

References (3)

Frequently Asked Questions